Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Human Papillomavirus Infection Among Pregnant Women Living With HIV: A Systematic Review and Meta-Analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. HIV infection is associated with type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Alterations in the kynurenine pathway of tryptophan metabolism are associated with depression in people living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Observational cohort study of rilpivirine (RPV) utilization in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Despite increased integrase strand transfer inhibitor (INSTI) use, limited large-scale, real-life data exists on INSTI uptake and discontinuation.

SETTING: International multicohort collaboration.

METHODS: RESPOND participants starting dolutegravir (DTG), elvitegravir (EVG), or raltegravir (RAL) after January 1, 2012 were included. Predictors of INSTI used were assessed using multinomial logistic regression. Kaplan-Meier and Cox proportional hazards models describe time to and factors associated with discontinuation.

RESULTS: Overall, 9702 persons were included; 5051 (52.1%) starting DTG, 1933 (19.9%) EVG, and 2718 (28.0%) RAL. The likelihood of starting RAL or EVG vs DTG decreased over time and was higher in Eastern and Southern Europe compared with Western Europe. At 6 months after initiation, 8.9% (95% confidence interval: 8.3% to 9.5%) had discontinued the INSTI (6.4% DTG, 7.4% EVG, and 14.0% RAL). The main reason for discontinuation was toxicity (44.2% DTG, 42.5% EVG, 17.3% RAL). Nervous system toxicity accounted for a higher proportion of toxicity discontinuations on DTG (31.8% DTG, 23.4% EVG, 6.6% RAL). Overall, treatment simplification was highest on RAL (2.7% DTG, 1.6% EVG, and 19.8% RAL). Factors associated with a higher discontinuation risk included increasing year of INSTI initiation, female gender, hepatitis C coinfection, and previous non-AIDS-defining malignancies. Individuals in Southern and Eastern Europe were less likely to discontinue. Similar results were seen for discontinuations after 6 months.

CONCLUSIONS: Uptake of DTG vs EVG or RAL increased over time. Discontinuation within 6 months was mainly due to toxicity; nervous system toxicity was highest on DTG. Discontinuation was highest on RAL, mainly because of treatment simplification.

TidsskriftJournal of acquired immune deficiency syndromes (1999)
Udgave nummer3
Sider (fra-til)240-250
Antal sider11
StatusUdgivet - 1 mar. 2020

ID: 59340124